SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting
SAB Biotherapeutics will present clinical data on its lead asset SAB-142 at two major scientific conferences in June 2026. The company will deliver an oral presentation at the American Diabetes Association’s Scientific Sessions in New Orleans on June 5, focusing on safety, pharmacokinetics, and immunogenicity following repeat dosing. A poster presentation will also be shown at the FOCIS 2026 Annual Meeting in San Francisco on June 10, highlighting positive clinical translation from a juvenile non-human primate study.
Key figures
- Drug Name
- SAB-142
- Phase Of Trial
- Phase 2b
- Trial name
- SAFEGUARD
- Topline data date
- 2H 2027
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.